Flucloxacillin-induced liver injury

Toxicology

Volumn 254, Issue 3, 2008, Pages 158-163

  Andrews, Elise ^a   Daly, Ann K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cytochrome P450; Drug induced liver injury; Flucloxacillin

Indexed keywords

CYTOCHROME P450 3A5; FARNESOID X RECEPTOR; FLUCLOXACILLIN; HLA ANTIGEN CLASS 2; PREGNANE X RECEPTOR;

BACTERIAL INFECTION; CHOLESTASIS; ENVIRONMENTAL FACTOR; FAMILIAL INTRAHEPATIC CHOLESTASIS TYPE 1 GENE; GENE; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; BILE ACIDS AND SALTS; CHOLESTASIS; EUROPE; FLOXACILLIN; GENETIC PREDISPOSITION TO DISEASE; HOMEOSTASIS; HUMANS; LIVER DISEASES;

EID: 56449104455     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2008.08.009     Document Type: Review

References (60)

1. Aithal G.P. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Expert Opin. Drug Saf. 3 (2004) 519-523
2. Aithal G.P., Ramsay L., Daly A.K., Sonchit N., Leathart J.B., Alexander G., Kenna J.G., Caldwell J., and Day C.P. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39 (2004) 1430-1440
3. Alvarez L., Jara P., Sanchez-Sabate E., Hierro L., Larrauri J., Diaz M.C., Camarena C., De la Vega A., Frauca E., Lopez-Collazo E., and Lapunzina P. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum. Mol. Genet. 13 (2004) 2451-2460
4. Andrade R.J., Lucena M.I., Alonso A., Garcia-Cortes M., Garcia-Ruiz E., Benitez R., Fernandez M.C., Pelaez G., Romero M., Corpas R., Duran J.A., Jimenez M., Rodrigo L., Nogueras F., Martin-Vivaldi R., Navarro J.M., Salmeron J., de la Cuesta F.S., and Hidalgo R. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39 (2004) 1603-1612
5. Ballatori N., Christian W.V., Lee J.Y., Dawson P.A., Soroka C.J., Boyer J.L., Madejczyk M.S., and Li N. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 42 (2005) 1270-1279
6. Belinsky M.G., Dawson P.A., Shchaveleva I., Bain L.J., Wang R., Ling V., Chen Z.S., Grinberg A., Westphal H., Klein-Szanto A., Lerro A., and Kruh G.D. Analysis of the in vivo functions of Mrp3. Mol. Pharmacol. 68 (2005) 160-168
7. Bohan A., and Boyer J.L. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin. Liver Dis. 22 (2002) 123-136
8. Brown S.J., and Desmond P.V. Hepatotoxicity of antimicrobial agents. Semin. Liver Dis. 22 (2002) 157-167
9. Bull L.N., van Eijk M.J., Pawlikowska L., DeYoung J.A., Juijn J.A., Liao M., Klomp L.W., Lomri N., Berger R., Scharschmidt B.F., Knisely A.S., Houwen R.H., and Freimer N.B. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat. Genet. 18 (1998) 219-224
10. Carey M.A., and van Pelt F.N. Immunochemical detection of flucloxacillin adduct formation in livers of treated rats. Toxicology 216 (2005) 41-48
11. Chiang J.Y. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr. Rev. 23 (2002) 443-463
12. Chitturi S., and Farrell G.C. Drug-induced cholestasis. Semin. Gastrointest. Dis. 12 (2001) 113-124
13. Daly A.K., Aithal G.P., Leathart J.B., Swainsbury R.A., Dang T.S., and Day C.P. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132 (2007) 272-281
14. Daly A.K., and Donaldson P.T. Genetics of liver disease. Int. Hepatol. Updates (2008)
15. Devereaux B.M., Crawford D.H., Purcell P., Powell L.W., and Roeser H.P. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic?. Eur. J. Clin. Pharmacol. 49 (1995) 81-85
16. Dring M.M., Goulding C.A., Trimble V.I., Keegan D., Ryan A.W., Brophy K.M., Smyth C.M., Keeling P.W., O'Donoghue D., O'Sullivan M., O'Morain C., Mahmud N., Wikstrom A.C., Kelleher D., and McManus R. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130 (2006) 341-348 (quiz 592)
17. Elferink R.O. Cholestasis. Gut 52 Suppl. 2 (2003) ii42-8
18. Eppens E.F., van Mil S.W., de Vree J.M., Mok K.S., Juijn J.A., Oude Elferink R.P., Berger R., Houwen R.H., and Klomp L.W. FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte. J. Hepatol. 35 (2001) 436-443
19. Fairley C.K., McNeil J.J., Desmond P., Smallwood R., Young H., Forbes A., Purcell P., and Boyd I. Risk factors for development of flucloxacillin associated jaundice. BMJ 306 (1993) 233-235
20. +/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology 110 (1996) 199-209
21. Gnerre C., Blattler S., Kaufmann M.R., Looser R., and Meyer U.A. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14 (2004) 635-645
22. Hautekeete M.L., Horsmans Y., Van Waeyenberge C., Demanet C., Henrion J., Verbist L., Brenard R., Sempoux C., Michielsen P.P., Yap P.S., Rahier J., and Geubel A.P. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 117 (1999) 1181-1186
23. Huwyler J., Wright M.B., Gutmann H., and Drewe J. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr. Drug Metab. 7 (2006) 119-126
24. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4 (2005) 489-499
25. Kindmark A., et al. Pharmacogenomics J. 8 3 (2008) 186-195
26. Kramer W G.H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Curr. Med. Chem. 13 (2006) 997-1061
27. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins P.B., Daly A., Wrighton S.A., Hall S.D., Maurel P., Relling M., Brimer C., Yasuda K., Venkataramanan R., Strom S., Thummel K., Boguski M.S., and Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27 (2001) 383-391
28. Lakehal F., Dansette P.M., Becquemont L., Lasnier E., Delelo R., Balladur P., Poupon R., Beaune P.H., and Housset C. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem. Res. Toxicol. 14 (2001) 694-701
29. Lamba J., Strom S., Venkataramanan R., Thummel K.E., Lin Y.S., Liu W., Cheng C., Lamba V., Watkins P.B., and Schuetz E. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin. Pharmacol. Ther. 79 (2006) 325-338
30. Lang C., Meier Y., Stieger B., Beuers U., Lang T., Kerb R., Kullak-Ublick G.A., Meier P.J., and Pauli-Magnus C. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genom. 17 (2007) 47-60
31. Liguori M.J., and Waring J.F. Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions. Expert Opin. Drug Metab. Toxicol. 2 (2006) 835-846
32. Lin Y.S., Dowling A.L., Quigley S.D., Farin F.M., Zhang J., Lamba J., Schuetz E.G., and Thummel K.E. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62 (2002) 162-172
33. Lobatto S., Dijkmans B.A., Mattie H., and Van Hooff J.P. Flucloxacillin-associated liver damage. Neth. J. Med. 25 (1982) 47-48
34. Maria V.A., and Victorino R.M. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 41 (1997) 534-540
35. McNeil J.J., Grabsch E.A., and McDonald M.M. Postmarketing surveillance: strengths and limitations. The flucloxacillin-dicloxacillin story. Med. J. Aust. 170 (1999) 270-273
36. Miros M., Kerlin P., Walker N., and Harris O. Flucloxacillin induced delayed cholestatic hepatitis. Aust. N. Z. J. Med. 20 (1990) 251-253
37. Mullenbach R., Bennett A., Tetlow N., Patel N., Hamilton G., Cheng F., Chambers J., Howard R., Taylor-Robinson S.D., and Williamson C. ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. Gut 54 (2005) 829-834
38. Noe J., Kullak-Ublick G.A., Jochum W., Stieger B., Kerb R., Haberl M., Mullhaupt B., Meier P.J., and Pauli-Magnus C. Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. J. Hepatol. 43 (2005) 536-543
39. O'Donohue J., Oien K.A., Donaldson P., Underhill J., Clare M., MacSween R.N., and Mills P.R. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47 (2000) 717-720
40. Pachkoria K., Lucena M.I., Crespo E., Ruiz-Cabello F., Lopez-Ortega S., Fernandez M.C., Romero-Gomez M., Madrazo A., Duran J.A., Malcon de Dios A., Borraz Y., Navarro J.M., Andrade R.J., and Disease S.G.f.t.S.o.D.I.L. Analysis of IL-10, IL-4 and TNFalpha polymorphisms in drug induced liver injury (DILI). J. Hepatol. 49 (2008) 107-114
41. Patel T., and Gores G.J. Apoptosis and hepatobiliary disease. Hepatology 21 (1995) 1725-1741
42. Pauli-Magnus C., Stieger B., Meier Y., Kullak-Ublick G.A., and Meier P.J. Enterohepatic transport of bile salts and genetics of cholestasis. J. Hepatol. 43 (2005) 342-357
43. Pawlikowska L., Groen A., Eppens E.F., Kunne C., Ottenhoff R., Looije N., Knisely A.S., Killeen N.P., Bull L.N., Elferink R.P., and Freimer N.B. A mouse genetic model for familial cholestasis caused by ATP8B1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion. Hum. Mol. Genet. 13 (2004) 881-892
44. Russmann S., Kaye J.A., Jick S.S., and Jick H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br. J. Clin. Pharmacol. 60 (2005) 76-82
45. Schuetz E.G., Beck W.T., and Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in the human colon carcinoma cells. Mol. Pharmacol. 49 (1996) 311-318
46. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., and Gonzalez F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102 (2000) 731-744
47. Stedman C.A., Liddle C., Coulter S.A., Sonoda J., Alvarez J.G., Moore D.D., Evans R.M., and Downes M. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 2063-2068
48. Thijssen H.H. Identification of the active metabolites of the isoxazolyl penicillins by means of mass-spectrometry. J. Antibiot. 32 (1979) 1033-1037
49. Thijssen H.H. Analysis of isoxazolyl penicillins and their metabolites in body fluids by high-performance liquid chromatography. J. Chromatogr. 183 (1980) 339-345
50. Thijssen H.H., and Wolters J. The metabolic disposition of flucloxacillin in patients with impaired kidney function. Eur. J. Clin. Pharmacol. 22 (1982) 429-434
51. Trauner M., and Boyer J.L. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 83 (2003) 633-671
52. Trauner M., Fickert P., and Zollner G. Genetic disorders and molecular mechanisms in cholestatic liver disease-a clinical approach. Semin. Gastrointest. Dis. 12 (2001) 66-88
53. Trauner M., Meier P.J., and Boyer J.L. Molecular pathogenesis of cholestasis. N. Engl. J. Med. 339 (1998) 1217-1227
54. Van Mil S.W., Milona A., Dixon P.H., Mullenbach R., Geenes V.L., Chambers J., Shevchuk V., Moore G.E., Lammert F., Glantz A.G., Mattsson L.A., Whittaker J., Parker M.G., White R., and Williamson C. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133 (2007) 507-516
55. Velayudham L.S., and Farrell G.C. Drug-induced cholestasis. Expert Opin. Drug Saf. 2 (2003) 287-304
56. Walgren J.L., Mitchell M.D., and Thompson D.C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35 (2005) 325-361
57. Welch K.D., Wen B., Goodlett D.R., Yi E.C., Lee H., Reilly T.P., Nelson S.D., and Pohl L.R. Proteomic identification of potential susceptibility factors in drug-induced liver disease. Chem. Res. Toxicol. 18 (2005) 924-933
58. Zhang J., Kuehl P., Green E.D., Touchman J.W., Watkins P.B., Daly A., Hall S.D., Maurel P., Relling M., Brimer C., Yasuda K., Wrighton S.A., Hancock M., Kim R.B., Strom S., Thummel K., Russell C.G., Hudson Jr. J.R., Schuetz E.G., and Boguski M.S. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11 (2001) 555-572
59. Zimmerman H.J. Drug-induced liver disease. Clin. Liver Dis. 4 (2000) 73-96
60. Zollner G., Wagner M., Fickert P., Geier A., Fuchsbichler A., Silbert D., Gumhold J., Zatloukal K., Kaser A., Tilg H., Denk H., and Trauner M. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. Am. J. Physiol. Gastrointest. Liver Physiol. 289 (2005) G798-G805